-
Skinmed 2015A 65-year-old woman was diagnosed with low-grade non-Hodgkin lymphoma (Figure 1). She was treated with six cycles of cyclophosphamide, hydroxydaunorubicin, oncovin...
A 65-year-old woman was diagnosed with low-grade non-Hodgkin lymphoma (Figure 1). She was treated with six cycles of cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), and prednisolone (CHOP) and three cycles of fludarabine and mitoxantrone. Ten months later she received radiotherapy to the left groin (total dose of 50 Gy in 25 fractions over 5 weeks) without complications.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Female; Humans; Lymphoma, Non-Hodgkin; Radiodermatitis
PubMed: 26861434
DOI: No ID Found -
Journal of the European Academy of... Jul 2001
Topics: Humans; Radiation Protection; Radiodermatitis
PubMed: 11730036
DOI: No ID Found -
Pediatric Dermatology Sep 2016Radiation recall dermatitis (RRD) is an uncommon reaction typically triggered by the use of chemotherapeutic agents in the months after treatment with radiation therapy....
Radiation recall dermatitis (RRD) is an uncommon reaction typically triggered by the use of chemotherapeutic agents in the months after treatment with radiation therapy. It usually presents as dermatitis in the irradiated field with prominent intertriginous involvement, and because internal involvement occurs in up to one-third of cases, early recognition is important. RRD has rarely been reported in the pediatric literature. We report the case of a 15-month-old boy with RRD to dactinomycin.
Topics: Antibiotics, Antineoplastic; Dactinomycin; Humans; Infant; Kidney Neoplasms; Male; Radiodermatitis; Rhabdoid Tumor
PubMed: 27377050
DOI: 10.1111/pde.12903 -
The Australasian Journal of Dermatology Nov 2019Radiation recall dermatitis is an acute inflammatory reaction that occurs on previously irradiated skin by usage of chemotherapeutic agents and other triggering drugs....
Radiation recall dermatitis is an acute inflammatory reaction that occurs on previously irradiated skin by usage of chemotherapeutic agents and other triggering drugs. The recall reaction is usually associated with drugs but may also occur following ultraviolet radiation. We report a patient with radiation recall dermatitis, triggered after imaging procedures that involved radiation.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoradiotherapy; Female; Humans; Middle Aged; Positron Emission Tomography Computed Tomography; Radiodermatitis; Sunlight
PubMed: 31012084
DOI: 10.1111/ajd.13037 -
Critical Reviews in Oncology/hematology Dec 2021Radiation recall reactions (RRR) are uncommon but are a well-known phenomenon to oncologists. Tissue damage in a prior irradiation portal is 'recalled' after the... (Review)
Review
Radiation recall reactions (RRR) are uncommon but are a well-known phenomenon to oncologists. Tissue damage in a prior irradiation portal is 'recalled' after the administration of a drug, historically cytotoxics, or more recently, targeted or immunotherapeutic agents. Even COVID-19 vaccines are a reported cause. RRR are enigmatic in that their cause is unknown, but they generally have the histopathological and clinical features of acute or chronic inflammation. They can occur in a variety of tissues, the commonest being skin, which accounts for two-thirds of reported cases. They are generally relatively mild and self-limiting once the trigger drug is stopped, although severe cases with tissue necrosis have occurred. Rechallenge with drug does not necessarily cause reactivation of the reaction. Symptomatic treatment with steroids and antihistamines are usually effective, but their impact on the clinical course is unclear. Various hypotheses have been proposed as to the mechanism of RRR; a non-immune fixed drug reaction-like condition, dysregulated release of reactive oxygen species, abnormalities of tissue vasculature and impaired DNA repair. All could lead to a characteristic inflammatory microenvironment, resulting in dysfunction of tissue stem cells, keratinocyte necrosis and dermal abnormalities. Alternatively or in addition, low levels of inflammatory tissue cytokines induced by previous irradiation might be further upregulated by drug exposure. Most information in this review refers to data derived from cutaneous RRR, since they are the most common form reported.
Topics: Antineoplastic Agents; COVID-19; COVID-19 Vaccines; Humans; Radiodermatitis; SARS-CoV-2
PubMed: 34808375
DOI: 10.1016/j.critrevonc.2021.103527 -
Radiation-Induced Skin Fibrosis: Pathogenesis, Current Treatment Options, and Emerging Therapeutics.Annals of Plastic Surgery Oct 2019Radiotherapy (RT) has become an indispensable part of oncologic treatment protocols for a range of malignancies. However, a serious adverse effect of RT is... (Review)
Review
Radiotherapy (RT) has become an indispensable part of oncologic treatment protocols for a range of malignancies. However, a serious adverse effect of RT is radiodermatitis; almost 95% of patients develop moderate to severe skin reactions following radiation treatment. In the acute setting, these can be erythema, desquamation, ulceration, and pain. Chronically, soft tissue atrophy, alopecia, and stiffness can be noted. Radiodermatitis can delay oncologic treatment protocols and significantly impair quality of life. There is currently a paucity of effective treatment options and prevention strategies for radiodermatitis. Importantly, recent preclinical and clinical studies have suggested that fat grafting may be of therapeutic benefit, reversing detrimental changes to soft tissue following RT. This review outlines the damaging effects of RT on the skin and soft tissue as well as discusses available treatment options for radiodermatitis. Emerging strategies to mitigate detrimental, chronic radiation-induced changes are also presented.
Topics: Fibrosis; Humans; Neoplasms; Quality of Life; Radiodermatitis; Radiotherapy
PubMed: 31513068
DOI: 10.1097/SAP.0000000000002098 -
Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report.Immunotherapy Feb 2020Radiation recall dermatitis (RRD) is an uncommon dermatologic reaction provoked notably by chemotherapy in an area of skin irradiated weeks to years prior. We report a...
Radiation recall dermatitis (RRD) is an uncommon dermatologic reaction provoked notably by chemotherapy in an area of skin irradiated weeks to years prior. We report a case of RRD with nivolumab in a woman with breast cancer. The patient was diagnosed with invasive ductal carcinoma of the left breast with an isolated spinal metastasis approached in an oligometastatic fashion with neoadjuvant chemotherapy, modified radical mastectomy and adjuvant radiotherapy. Unfortunately, after progression of bony metastases treated with radiotherapy, the patient received nivolumab and subsequently developed a rash corresponding to the adjuvant radiation field. This case highlights the unpredictable nature and characteristic rash of RRD. It is an important differential diagnosis for multidisciplinary teams who also see chemotherapy-induced dermatitis and immune-related adverse events.
Topics: Aged; Antineoplastic Agents, Immunological; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Nivolumab; Radiodermatitis; Radiotherapy, Adjuvant
PubMed: 31992119
DOI: 10.2217/imt-2019-0020 -
Dermatology (Basel, Switzerland) 2015The cutaneous effects of BRAF (serine/threonine protein kinase B-raf) inhibitors such as vemurafenib remain poorly defined. Rash, squamous cell carcinoma,... (Review)
Review
The cutaneous effects of BRAF (serine/threonine protein kinase B-raf) inhibitors such as vemurafenib remain poorly defined. Rash, squamous cell carcinoma, keratoacanthoma and photosensitivity are the most common grade 2 or 3 adverse events observed in clinical trials. We here report the case of a patient with a BRAF V600E mutated metastatic melanoma who developed severe radiation recall dermatitis 6 weeks after completing radiotherapy. Vemurafenib treatment had been initiated 1 week before the development of dermatitis because of rapidly progressing disease. Upon topical treatment of the affected skin areas, clinical symptoms regressed over a period of 2 months, although vemurafenib was continuously administered. As our case goes in line with other reports, we believe that physicians should be aware of this additional cutaneous side effect of vemurafenib and that continuation of the treatment is safe when close clinical control and interdisciplinary management can be provided.
Topics: Aged; Humans; Indoles; Male; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiodermatitis; Skin Neoplasms; Sulfonamides; Vemurafenib
PubMed: 25472806
DOI: 10.1159/000365918 -
Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug?The British Journal of Dermatology Sep 2005
Review
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Contraindications; Docetaxel; Female; Humans; Middle Aged; Radiation-Sensitizing Agents; Radiodermatitis; Taxoids
PubMed: 16120169
DOI: 10.1111/j.1365-2133.2005.06801.x -
International Journal of Dermatology Apr 2017
Topics: Adult; Antineoplastic Agents, Immunological; Bone Neoplasms; Humans; Lymphatic Metastasis; Male; Melanoma; Nivolumab; Radiodermatitis; Skin Neoplasms
PubMed: 28102540
DOI: 10.1111/ijd.13513